For patients with nonvalvular atrial fibrillation, a key question has emerged beyond stroke prevention: does our choice of direct oral anticoagulant, or DOAC, influence long-term dementia risk? A landmark study provides a clear answer.

For patients with nonvalvular atrial fibrillation, a key question has emerged beyond stroke prevention: does our choice of direct oral anticoagulant, or DOAC, influence long-term dementia risk? A landmark study provides a clear answer.

New baby food rules require public testing for lead, arsenic, cadmium, and mercury, improving transparency, guiding safer choices, and encouraging manufacturers to reduce contamination.

Direct Oral Anticoagulants and Dementia Risk in Nonvalvular Atrial Fibrillation: Evidence to Guide Clinical Selection

Large real-world study found no meaningful dementia risk differences between apixaban, edoxaban, and rivaroxaban, supporting DOAC selection based on safety, adherence, renal function, and patient needs.

Direct Oral Anticoagulants and Dementia Risk in Nonvalvular Atrial Fibrillation: Evidence to Guide Clinical Selection

Large real-world study found apixaban, edoxaban, and rivaroxaban offer similar dementia protection in atrial fibrillation, allowing clinicians to prioritize safety, adherence, and patient-specific factors.

Beyond the Prescription Pad: Breast Cancer Survivorship via Combined Lifestyle Interventions

A structured low-GI Mediterranean diet, daily brisk walking, and vitamin D supplementation significantly reduced recurrence risk in HR-positive breast cancer survivors while improving metabolic health.

Adagio Files FDA Submission For Ventricular Ablation System

Adagio Medical’s FDA submission for its ultra-low temperature ventricular ablation system could expand treatment options for drug-refractory ventricular tachycardia, offering deeper lesion creation, fewer ICD shocks, reduced antiarrhythmic dependence, and improved procedural outcomes.